Skip to content

Role of Immunohistochemistry Markers in Gynecologic cancers

Role of IHC Markers in Gynecologic cancers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055260
Enrollment
150
Registered
2023-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C51-C58- Malignant neoplasms of female genital organs

Interventions

None listed

Sponsors

Kasturba Medical College and Kasturba Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women with biopsy proven cervical, Endometrial, and Ovarian Cancers Woman with Cervical pre-cancers and borderline ovarian tumours Woman with uterine sarcomas

Exclusion criteria

Exclusion criteria: Women who have already started treatment Women referred with biopsy report and no further IHC evaluation suggested

Design outcomes

Primary

MeasureTime frame
Outcome of the study is to find the indications to do IHC Markers in the biopsy specimens (Tests will be done at the discretion of the treating clinician and pathologist)Timepoint: Hence IHC is only done at one time point when the pathologist or clinician decides during the evaluation of the biopsy specimen

Secondary

MeasureTime frame
Use the relevant markers as a guide to dictate diagnosis, treatment protocol & Prognosis.Timepoint: Hence IHC is only done at one time point when the pathologist or clinician decides during the evaluation of the biopsy specimen

Countries

India

Contacts

Public ContactDr Sonika Gupta

Kasturba Medical College, Manipal

shyamala.g@manipal.edu9844551037

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 19, 2026